Neuren Pharmaceuticals (ASX:NEU)
Neuren Pharmaceuticals is a Melbourne-based drug developer. The company’s lead compound is Trofinetide, for the treatment of two Autism Spectrum Disorders, Rett Syndrome and Fragile X Syndrome. The company has generated favourable Phase 2 data in both these conditions.
5/12/2018 In Phase 3, priced like Phase 2